Private investment platform Blackstone closed a funding raise that has brought in $6.3bn in capital to support its ongoing life sciences investment strategy – marking the largest life sciences private fund ever raised.
The firm’s dedicated BXLS platform will absorb this oversubscribed funding round, providing companies with capital to develop and commercialise new drugs and medical technologies across the entire lifecycle.
In the last 12 months, BXLS has handed over nearly $2bn to various companies within the life sciences sector to fund their development and commercialisation journeys. This includes MSD (Merck & Co), which recently bagged $700m to support the development of its antibody-drug conjugate (ADC), sacituzumab tirumotecan, across various solid tumour indications.
BXLS also poured $400m into Teva Pharmaceutical’s duvakitug development programme back in early March 2026, which is currently in late-stage trials for inflammatory bowel diseases like Crohn’s and ulcerative colitis.
In February 2026, the investment platform teamed up with Johnson & Johnson (J&J) to co-fund future clinical trials of its acute myeloid leukaemia (AML) drug, bleximenib.
Blackstone Life Sciences has previously secured 34 approvals for innovative medicines and devices it has backed, including blockbuster therapies like Alnylam Pharmaceuticals’ transthyretin amyloidosis (ATTR) therapy, Amvuttra (vutrisiran) and AbbVie & J&J’s Bruton’s tyrosine kinase (BTK) inhibitor, Imbruvica (ibrutinib).
Taking a look at the life sciences investment landscape
According to Blackstone Life Sciences’ global head, Nicholas Galakatos, this round highlights the firm’s “enduring conviction in the life sciences”, which remains one of its core areas of focus.
This will be welcome news for the sector, which has been contending with a challenging funding landscape triggered by burgeoning interest rates and economic uncertainty in recent years. Geopolitical factors like tariffs are also currently shaping pharmaceutical investment and launch strategies.
Despite these hurdles, there have been some positive signals hinting to the recovery of pharma funding. As per a report from GlobalData, parent company of Pharmaceutical Technology, the total value of venture capital investments made in the sector in Q4 2025 climbed 70.6% compared with Q3. This upward trend was also observed in the volume of investments, which saw a 30.4% uptick to 206 deals.
GlobalData has also highlighted the shift in investor activity – especially in the cell and gene therapy (CGT) space – which has seen an enhanced interest in candidates in the Series B-stage, as investors become more selective and strategy-driven.
In a previous conversation with Pharmaceutical Technology, LanceBio Ventures partner, Ilya Yasny, noted that early planning, adaptability, trust building and strong data make up the backbone of any successful startup, and that companies should always look to fulfil an unmet patient need.
